Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 known ✓ | Q9BY41 | 3/20 | 0.45 |
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.45 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.45 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 2/20 | 0.45 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC10 known ✓ | Q969S8 | 2/20 | 0.45 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 2/20 | 0.45 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 2/20 | 0.45 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 2/20 | 0.45 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.42 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.42 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.42 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10848541 | 0.99 | TBXAS1 (0.53) | TBXAS1TAAR1HDAC8HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL11261045 | 0.99 | TBXAS1 (0.53) | TBXAS1TAAR1HDAC8HDAC3HDAC4 | |
| SCHEMBL9507338 | 0.99 | TAAR1 (0.55) | TBXAS1TAAR1HDAC8HDAC3HDAC4 | |
| SCHEMBL9401700 | 0.99 | TAAR1 (0.55) | TBXAS1TAAR1HDAC8HDAC3HDAC4 | |
| SCHEMBL11107735 | 0.83 | CA12 (0.49) | TAAR1HDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL11260195 | 0.82 | CA12 (0.55) | TAAR1HDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL10845162 | 0.82 | CA12 (0.55) | TAAR1HDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL11476379 | 0.81 | NPC1 (0.51) | TAAR1HDAC8HDAC3HDAC4HDAC1 | |
| SCHEMBL8319084 | 0.80 | TAAR1 (0.43) | TBXAS1TAAR1HDAC8HDAC3HDAC4 | |
| SCHEMBL7299851 | 0.79 | TAAR1 (0.62) | TAAR1LMNACYP2D6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0058079-B1 | 4-(1-IMIDAZOLYLMETHYL)CINNAMIC ACID HYDROCHLORIDE MONOHYDRATE, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kissei Pharmaceutical Co. Ltd. (JP) | 1985-01-23 | — | — | EP | claimed |
| JP-57131769-A | — | — | None | — | — | JP | disclosed |
| EP-0294814-B1 | Treating agents for renal diseases | DAIICHI SEIYAKU CO (JP) | 1994-01-12 | — | — | EP | disclosed |
| EP-0298465-B1 | ANTIDIABETIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-02-17 | — | — | EP | disclosed |
| US-4942171-A | The compound, 6-(1-imidazolyl methyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid and salts thereof having antidiabetic activity | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-07-17 | — | — | US | disclosed |
| EP-0135177-B1 | BENZOCYCLOALKANE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-12-06 | — | — | EP | disclosed |
| EP-0298465-A2 | Antidiabetic agent | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1989-01-11 | — | — | EP | disclosed |
| EP-0294814-A2 | Treating agents for renal diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1988-12-14 | — | — | EP | disclosed |
| US-4777257-A | CARDIOVASCULAR DISORDERS | DAIICHI SEIYAKU CO., LTD. (JP) | 1988-10-11 | — | — | US | disclosed |
| US-4665188-A | Certain [(1-imidazolyl)-lower-alkylene]-tetrahydronaphthalenecarboxylic acids or corresponding idan-carboxylic acids which are thromboxane A2 | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| US-4607046-A | THROMBOXANE SYNTHETASE INHIBITOR | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1986-08-19 | — | — | US | disclosed |
| EP-0135177-A2 | Benzocycloalkane derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-03-27 | — | — | EP | disclosed |
| EP-0058079-B1 | 4-(1-IMIDAZOLYLMETHYL)CINNAMIC ACID HYDROCHLORIDE MONOHYDRATE, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kissei Pharmaceutical Co. Ltd. (JP) | 1985-01-23 | — | — | EP | disclosed |
| EP-0058079-A2 | 4-(1-Imidazolylmethyl)cinnamic acid hydrochloride monohydrate, method of preparation thereof, and pharmaceutical composition containing same | Kissei Pharmaceutical Co. Ltd. (JP) | 1982-08-18 | — | — | EP | disclosed |
| JP-S57131769-A | 4-(1-IMIDAZOLYLMETHYL)CINNAMIC ACID HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND DRUG CONTAINING THE SAME | KISSEI PHARMACEUT CO LTD | 1982-08-14 | — | — | JP | disclosed |
| US-4226878-A | ANTIINFLAMMATORY, HYPOTENSIVES, ANTIHISTAMINES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1980-10-07 | — | — | US | disclosed |